Table 2.

Potential prognostic factors for molecular relapse: univariate analysis

VariableCumulative incidence of relapse by 48 mo (95% CI)Overall P value
Age0.154
 >60 y (n = 28)54.78% (38.85-77.24)
  ≤60 y (n = 32)36.72% (22.49-59.95)
Sex0.577
 Male (n = 22)36.36% (20.92-63.2)
 Female (n = 38)49.66% (35.45-69.55)
Sokal score0.623
 Low (n = 32)42.71% (27.88-65.3)
 Intermediate + high (n = 25)49.1% (33.07-74.74)
Prior IFN-α0.637
 Yes (n = 17)41.76% (23.67-73.7)
 No (n = 43)45.94% (32.65-64.64)
TKI treatment duration0.643
 >76 mo (n = 30)47.11% (32.13-69.08)
  ≤76 mo (n = 30)42.29% (27.10-66)
2G-TKI treatment duration0.772
 >39 mo (n = 29)44.83% (29.94-67.13)
  ≤39 mo (n = 31)44.31% (29.22-67.19)
uMR4.5 duration0.597
 >29 mo (n = 29)37.93% (23.81-60.42)
  ≤29 mo (n = 31)50.52% (35.13-72.66)
2G-TKI type0.331
 Dasatinib (n = 30)50.83% (35.52-72.76)
 Nilotinib (n = 30)38.62% (29.99-62.15)
Prior intolerance or resistance to TKI0.00233
 Yes (n = 13)35.51% (23.73-53.15)
 No (n = 47)76.92% (57.11-100)
  • Quantitative variables were categorized into 2 groups with cutoffs set at median. P < .05 was considered statistically significant.